BWAY Brainsway

BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024

BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024

BURLINGTON, Mass. and JERUSALEM, April 24, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:Wednesday, May 8, 2024
Time:8:30 AM Eastern Time
United States:1-888-886-7786
International:1-416-764-8658
Conference ID:50552862
Webcast:



The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, . Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit .

Contacts: 

BrainsWay:

Ido Marom

Chief Financial Officer

Investors:

Brian Ritchie

LifeSci Advisors LLC



EN
24/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Brainsway

 PRESS RELEASE

BrainsWay Reports First Quarter 2024 Financial Results and Operational...

BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights Generated Significant 37% Year-over-Year Revenue Growth in Q1 2024 Recorded Positive Quarterly Net Income for Second Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Third Consecutive Quarter Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 08, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported first quart...

 PRESS RELEASE

BrainsWay to Report First Quarter 2024 Financial Results on May 8, 202...

BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024 BURLINGTON, Mass. and JERUSALEM, April 24, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and pr...

 PRESS RELEASE

BrainsWay Expands Deep TMS™ Access in Israel Following Significant Inc...

BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates Company Announces 11th Recent System Installed in Israel, with More Expected this Year BURLINGTON, Mass. and JERUSALEM, April 17, 2024 (GLOBE NEWSWIRE) --  BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the further expansion of access to its Deep TMS™ treatment in Israel. BrainsWay has steadily increased its presence in the country with 11 recent system ins...

 PRESS RELEASE

BrainsWay Announces Published Review Results Highlighting Potential of...

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor Symptoms JERUSALEM and BURLINGTON, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced results published in a review article exploring the potential efficacy of Deep Transcranial Magnetic Stimulation (Deep TMS™) as a novel therapeutic...

 PRESS RELEASE

BrainsWay Announces Positive Results in Late-Life Depression Post-Mark...

BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis Data Published in Leading Peer-Reviewed Publication, Journal of Clinical Medicine JERUSALEM and BURLINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced positive results in a recently published post-marketing study of its Deep Transcranial Magnetic Stimulation (Deep TMS™) for the treatment of late-life depression. The data were high...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch